Last reviewed · How we verify
Adebrelimab (PD-L1 inhibitor)
Adebrelimab blocks the PD-L1 checkpoint protein on tumor cells, preventing it from suppressing anti-tumor immune responses and allowing T cells to attack cancer.
Adebrelimab blocks the PD-L1 checkpoint protein on tumor cells, preventing it from suppressing anti-tumor immune responses and allowing T cells to attack cancer. Used for Non-small cell lung cancer (NSCLC), Other solid tumors (under investigation in Phase 3).
At a glance
| Generic name | Adebrelimab (PD-L1 inhibitor) |
|---|---|
| Also known as | SHR-A1316 |
| Sponsor | Sun Yat-sen University |
| Drug class | PD-L1 inhibitor |
| Target | PD-L1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Adebrelimab is a monoclonal antibody that binds to programmed death ligand 1 (PD-L1) on the surface of tumor cells and immune cells. By blocking the PD-L1/PD-1 interaction, it releases the brake on T cell-mediated anti-tumor immunity, enabling cytotoxic T lymphocytes to recognize and eliminate cancer cells. This mechanism is similar to other PD-L1 inhibitors and represents a form of immune checkpoint inhibition.
Approved indications
- Non-small cell lung cancer (NSCLC)
- Other solid tumors (under investigation in Phase 3)
Common side effects
- Fatigue
- Decreased appetite
- Immune-related adverse events (irAEs)
- Pneumonitis
- Hepatotoxicity
Key clinical trials
- Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer (PHASE1, PHASE2)
- A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC
- Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC) (PHASE2)
- Adebrelimab Neoadjuvant Treatment for Resectable ESCC (NA)
- Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer (PHASE2)
- Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) (PHASE2)
- SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC (PHASE2)
- A Study of SHR-A1811 Combined With Adebelimumab as Neoadjuvant Therapy for Resectable HER2-Altered Non-Small Cell Lung Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adebrelimab (PD-L1 inhibitor) CI brief — competitive landscape report
- Adebrelimab (PD-L1 inhibitor) updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI